|
KMID : 0606920030110030163
|
|
Biomolecules & Therapeutics
2003 Volume.11 No. 3 p.163 ~ p.168
|
|
|
Pharmacokinetics of a New Antigastritic Agent, Eupatilin, an Active Component of Stillen/sup (R)/, in Rats
|
|
Jang JM
Park KJ/Kim DG/Shim HJ/Ahn BO/Kim SH/Kim WB
|
|
|
Abstract
|
|
|
|
Pharmacokinetics of eupatilin (an active components of Stillen/sup /, a new antigastritic agent) were investigated after both intravenous and oral administration at a dose of 30㎎/㎏ to rats. After intravenous administration, the plasma concentrations of unchanged eupatilin declined rapidly with a mean terminal half-life of 0.101 h. Eupatilin was eliminated fast in rats; the total body clearance was 121 mL/min/㎏. Eupatilin was mainly metabolized in rats; the percentage of intravenous dose of eupatilin excreted in 24 h urine and feces as unchanged eupatilin was only 2.5 and 0.919％, respectively. Eupatilin was mainly metabolized to form its glucuronide conjugate; after intravenous administration, 15.9 and 51.7％ of intravenous dose was excreted in 24 h urine and feces, respectively, as eupatilin plus its glucuronide. After oral administration, the absolute bioavailability was only 3.86％ based on AUC/sub 0-24h/ of eupatilin plus its glucuronide. Approximately 68.5％ of oral dose was not absorbed from the entire gastrointestinal tract. Therefore, it could be concluded that the superior effect of eupatilin in experimental animal models of gastric ulcer and inflammatory bowel disease after oral administration could be due to the local action of eupatilin. Further pharmacokinetic studies to elucidate the local action of eupatilin are required.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|